GlassScriptPhysician profile
Madhav Suri
NPI 1669456539
$12,202.99
in general payments reported to CMS, 2019-2025
51 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,370 · 2020: $1,757 · 2021: $1,430 · 2022: $1,084 · 2023: $1,324 · 2024: $1,391 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,561.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,776.85 | 2021-2025 | Qulipta, Ubrelvy |
| Ucb, INC. | $1,085.02 | 2019-2025 | Briviact, Fintepla |
| Teva Pharmaceuticals USA, INC. | $861.09 | 2019-2025 | Austedo Xr |
| Livanova USA, INC. | $801.26 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $684.45 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $584.00 | 2019-2021 | |
| Pfizer INC. | $497.34 | 2021-2025 | |
| Sk Life Science, INC. | $386.87 | 2020-2025 | Xcopri |
| Lilly USA, LLC | $374.43 | 2019-2023 | Emgality, Reyvow |
| Amgen INC. | $359.04 | 2019-2025 | Uplizna |
| Kyowa Kirin, INC. | $346.97 | 2020-2023 | Nourianz |
| Allergan, INC. | $276.38 | 2020-2022 | |
| Lundbeck LLC | $274.31 | 2020-2025 | Vyepti |
| Akcea Therapeutics, INC. | $249.52 | 2019 | |
| Supernus Pharmaceuticals, INC. | $246.27 | 2019-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhav Suri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.